GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » ROA %

AMAG Pharmaceuticals (AMAG Pharmaceuticals) ROA % : 5.35% (As of Sep. 2020)


View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. AMAG Pharmaceuticals's annualized Net Income for the quarter that ended in Sep. 2020 was $38.8 Mil. AMAG Pharmaceuticals's average Total Assets over the quarter that ended in Sep. 2020 was $725.0 Mil. Therefore, AMAG Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2020 was 5.35%.

The historical rank and industry rank for AMAG Pharmaceuticals's ROA % or its related term are showing as below:

AMAG's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -35.515
* Ranked among companies with meaningful ROA % only.

AMAG Pharmaceuticals ROA % Historical Data

The historical data trend for AMAG Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AMAG Pharmaceuticals ROA % Chart

AMAG Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 -0.10 -9.17 -4.45 -47.56

AMAG Pharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.62 -91.09 -12.68 -7.21 5.35

Competitive Comparison of AMAG Pharmaceuticals's ROA %

For the Biotechnology subindustry, AMAG Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AMAG Pharmaceuticals's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AMAG Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where AMAG Pharmaceuticals's ROA % falls into.



AMAG Pharmaceuticals ROA % Calculation

AMAG Pharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2019 is calculated as:

ROA %=Net Income (A: Dec. 2019 )/( (Total Assets (A: Dec. 2018 )+Total Assets (A: Dec. 2019 ))/ count )
=-467.661/( (1175.459+791.227)/ 2 )
=-467.661/983.343
=-47.56 %

AMAG Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2020 is calculated as:

ROA %=Net Income (Q: Sep. 2020 )/( (Total Assets (Q: Jun. 2020 )+Total Assets (Q: Sep. 2020 ))/ count )
=38.808/( (715.549+734.356)/ 2 )
=38.808/724.9525
=5.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2020) net income data. ROA % is displayed in the 30-year financial page.


AMAG Pharmaceuticals  (NAS:AMAG) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Sep. 2020 )
=Net Income/Total Assets
=38.808/724.9525
=(Net Income / Revenue)*(Revenue / Total Assets)
=(38.808 / 372.424)*(372.424 / 724.9525)
=Net Margin %*Asset Turnover
=10.42 %*0.5137
=5.35 %

Note: The Net Income data used here is four times the quarterly (Sep. 2020) net income data. The Revenue data used here is four times the quarterly (Sep. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


AMAG Pharmaceuticals ROA % Related Terms

Thank you for viewing the detailed overview of AMAG Pharmaceuticals's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Winter Street, Waltham, MA, USA, 02451
AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.
Executives
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano officer: Chief Operating Officer C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos officer: Interim CFO C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson director, 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat director
Davey Scoon director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers director, officer: President & CEO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick officer: Chief Human Resources Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Headlines

From GuruFocus

Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals

By Marketwired Marketwired 10-01-2020

Covis Group Completes Acquisition of AMAG Pharmaceuticals

By PRNewswire PRNewswire 11-16-2020